Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

By M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe and 8 more. New England Journal of Medicine, 2016

8,730 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/39c4eedbb210d0eb3aac3a08889807425bafbd27

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Wolchok
2. Nicholas McGranahan
3. C. Robert
4. M. Hellmann
5. K. Kerr
6. M. Callahan
7. M. Sanmamed
8. K. Flaherty

In Pulmonary and Respiratory Medicine

1. J. Gong
2. Charles Swanton
3. S. Reddi
4. Alexander Chehrazi-Raffle
5. Ravi Salgia
6. Nicholas McGranahan

Citations in the corpus

• Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020, background): “This trial was stopped early to allow patients who were still on chemotherapy the opportunity to receive pembrolizumab [51].”
• STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma (2018, neutral): “KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”